Polaryx Therapeutics’ mission is to meet the large unmet need and accelerate the availability of treatments for patients and families living with lysosomal storage disorders (LSDs). Our pipeline is comprised of uniquely formulated refocused drugs, New Chemical Entities (NCE), and gene therapy candidates to treat these diseases. 

There is an urgent need for novel therapeutic interventions for LSDs, including Neuronal Ceroid Lipofuscinosis, Krabbe Disease, Sandhoff Disease, and Niemann-Pick Type A / B Diseases. Polaryx was founded in 2014 with the singular aim of addressing these unmet needs with a strong scientific basis and patient-friendly routes of administration.

Polaryx Therapeutics

Org chart

Teams

Offices